Similar articles

• Comment on the article titled "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes".

  Wen J, Chen J, Fan M. Wen J, et al. Lung Cancer. 2019 Nov;137:157-158. doi: 10.1016/j.lungcan.2019.07.026. Epub 2019 Aug 12. Lung Cancer. 2019. PMID: 31521423 No abstract available.
• Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.

  Ng TL, Liu Y, Dimou A, Patil T, Aisner DL, Dong Z, Jiang T, Su C, Wu C, Ren S, Zhou C, Camidge DR. Ng TL, et al. Cancer. 2019 Apr 1;125(7):1038-1049. doi: 10.1002/cncr.31871. Epub 2018 Dec 11. Cancer. 2019. PMID: 30548240
• About concomitant KRAS and other molecular alterations in non-small cell lung cancers.

  Bourhis A, Quintin-Roué I, Uguen A. Bourhis A, et al. Hum Pathol. 2019 May;87:115-116. doi: 10.1016/j.humpath.2019.01.003. Epub 2019 Feb 20. Hum Pathol. 2019. PMID: 30796937 No abstract available.
• The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.

  Qu Y, Che N, Zhao D, Zhang C, Su D, Zhou L, Zhang L, Wang C, Zhang H, Wei L. Qu Y, et al. Tumour Biol. 2015 Aug;36(8):6417-24. doi: 10.1007/s13277-015-3331-4. Epub 2015 Mar 28. Tumour Biol. 2015. PMID: 25813151
• KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives.

  Guibert N, Ilie M, Long E, Hofman V, Bouhlel L, Brest P, Mograbi B, Marquette CH, Didier A, Mazieres J, Hofman P. Guibert N, et al. Curr Mol Med. 2015;15(5):418-32. doi: 10.2174/1566524015666150505161412. Curr Mol Med. 2015. PMID: 25941815 Review.